Placebo for comparator product Apixaban 2.5mg clinical trials

(19767 OCEANIC-AF) A multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy, parallel-group, 2-arm, Phase 3 study to compare the efficacy and safety of the oral FXIa inhibitor asundexian (BAY 2433334) with apixaban for the prevention of stroke or systemic embolism in male and female participants aged 18 years and older with atrial fibrillation at risk for stroke

This study is testing a new medication called asundexian against a standard treatment (apixaban) to see how well it prevents strokes or serious blood clots in people with atrial fibrillation, a type of irregular heartbeat. It's also looking at how safe the new drug is.